Application No. 10/701,295 Amendment dated October 11, 2006 Reply to Office Action of May 11, 2006

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the

application:

1-20. Canceled

21. (Currently amended) A dosage form for topical treatment of a bacterial, viral or

fungal infection in a patient in need thereof, said dosage form comprising:

a pharmaceutically acceptable acidifying agent consisting of an organic acid and a pharmaceutically acceptable carrier, said organic acid in an amount sufficient to

establish a pH at an environment of use below 4, and

a pharmaceutically acceptable source of nitrite ions, in an amount effective when

combined with said organic acidifying agent to treat said infection,

wherein said acidifying agent and said source of nitrite ions are disposed separately

in respective pharmaceutically acceptable carriers for admixture at the intended

environment of use and being effective to release NO or NO2 at the environment of

use and wherein said dosage form is in the form of a paint, a varnish, an ointment, a

wax, a salve, a cream, or is impregnated in a film or a gauze.

 (Previously presented) The dosage form of claim 21, wherein said organic acid is selected from the group consisting of ascorbic acid, ascorbyl palmitate, salicylic

acid, lactic acid, citric acid, formic acid, benzoic acid and tartaric acid.

23. (Previously presented) The dosage form of claim 22, wherein said organic acid is

salicylic acid or ascorbic acid.

2

Application No. 10/701,295 Amendment dated October 11, 2006 Reply to Office Action of May 11, 2006

- 24. (Previously presented) The dosage form of claim 22, wherein said organic acid is present in the first component at a concentration from 0.5% to 30% by weight for ascorbic acid, ascorbyl palmitate, salicylic acid, lactic acid, formic acid, benzoic acid and tartaric acid or from 0.5% to 45% by weight for citric acid or salicylic acid.
- 25. (Currently amended) The dosage form of claim 21, wherein said metal alkali nitrite pharmaceutically acceptable source of nitrite ions is sodium nitrite.
- 26. (Previously presented) The dosage form of claim 24, wherein said sodium nitrite is present in the second component at a concentration from 0.5 to 30% by weight.
- 27. (Currently amended) The dosage form of claim 21 wherein said organic acid is selected from the group consisting of ascorbic acid at a concentration of from 1 to 10% by weight of ascorbic acid, ascorbyl palmitate at a concentration from 3 to 25% by weight of ascorbyl palmitate, salicylic acid at a concentration from 0.5 to 44 % by weight, and citric acid at a concentration up to 45% by weight.